Novo Nordisk A/S (NYSE: NVO) Stock Competitors & Peer Comparison

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 202.9B. In comparison, LLY has a market cap of 1.2T. Regarding current trading prices, NVO is priced at $45.71 on the NYSE, while LLY trades at $1,225.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 11.37, whereas LLY's P/E ratio is 38.95. In terms of profitability, NVO's ROE is +0.59%, compared to LLY's ROE of +0.93%. Regarding short-term risk, NVO is more volatile compared to LLY. This indicates higher risk in terms of short-term price fluctuations for NVO.Check LLY's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 202.9B. In comparison, JNJ has a market cap of 653.4B. Regarding current trading prices, NVO is priced at $45.71 on the NYSE, while JNJ trades at $271.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 11.37, whereas JNJ's P/E ratio is 25.27. In terms of profitability, NVO's ROE is +0.59%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, NVO is more volatile compared to JNJ. This indicates higher risk in terms of short-term price fluctuations for NVO.Check JNJ's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 202.9B. In comparison, ABBV has a market cap of 457.5B. Regarding current trading prices, NVO is priced at $45.71 on the NYSE, while ABBV trades at $258.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 11.37, whereas ABBV's P/E ratio is 25.41. In terms of profitability, NVO's ROE is +0.59%, compared to ABBV's ROE of -1.36%. Regarding short-term risk, NVO is more volatile compared to ABBV. This indicates higher risk in terms of short-term price fluctuations for NVO.Check ABBV's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 202.9B. In comparison, MRK has a market cap of 333.8B. Regarding current trading prices, NVO is priced at $45.71 on the NYSE, while MRK trades at $135.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 11.37, whereas MRK's P/E ratio is 42.11. In terms of profitability, NVO's ROE is +0.59%, compared to MRK's ROE of +0.07%. Regarding short-term risk, NVO is more volatile compared to MRK. This indicates higher risk in terms of short-term price fluctuations for NVO.Check MRK's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 202.9B. In comparison, NVS has a market cap of 293.9B. Regarding current trading prices, NVO is priced at $45.71 on the NYSE, while NVS trades at $154.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 11.37, whereas NVS's P/E ratio is 17.79. In terms of profitability, NVO's ROE is +0.59%, compared to NVS's ROE of +0.30%. Regarding short-term risk, NVO is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for NVO.Check NVS's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 202.9B. In comparison, AZN has a market cap of 248.3B. Regarding current trading prices, NVO is priced at $45.71 on the NYSE, while AZN trades at $160.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 11.37, whereas AZN's P/E ratio is 17.29. In terms of profitability, NVO's ROE is +0.59%, compared to AZN's ROE of +0.22%. Regarding short-term risk, NVO is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for NVO.Check AZN's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 202.9B. In comparison, AMGN has a market cap of 229.5B. Regarding current trading prices, NVO is priced at $45.71 on the NYSE, while AMGN trades at $425.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 11.37, whereas AMGN's P/E ratio is 19.01. In terms of profitability, NVO's ROE is +0.59%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, NVO is more volatile compared to AMGN. This indicates higher risk in terms of short-term price fluctuations for NVO.Check AMGN's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 202.9B. In comparison, GILD has a market cap of 178.1B. Regarding current trading prices, NVO is priced at $45.71 on the NYSE, while GILD trades at $143.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 11.37, whereas GILD's P/E ratio is -367.79. In terms of profitability, NVO's ROE is +0.59%, compared to GILD's ROE of -0.16%. Regarding short-term risk, NVO is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for NVO.Check GILD's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 202.9B. In comparison, PFE has a market cap of 155.4B. Regarding current trading prices, NVO is priced at $45.71 on the NYSE, while PFE trades at $27.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 11.37, whereas PFE's P/E ratio is 8.94. In terms of profitability, NVO's ROE is +0.59%, compared to PFE's ROE of +0.05%. Regarding short-term risk, NVO is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for NVO.Check PFE's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 202.9B. In comparison, BMY has a market cap of 132.1B. Regarding current trading prices, NVO is priced at $45.71 on the NYSE, while BMY trades at $66.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 11.37, whereas BMY's P/E ratio is 10.90. In terms of profitability, NVO's ROE is +0.59%, compared to BMY's ROE of +0.47%. Regarding short-term risk, NVO is more volatile compared to BMY. This indicates higher risk in terms of short-term price fluctuations for NVO.Check BMY's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 202.9B. In comparison, SNY has a market cap of 108B. Regarding current trading prices, NVO is priced at $45.71 on the NYSE, while SNY trades at $44.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 11.37, whereas SNY's P/E ratio is 9.80. In terms of profitability, NVO's ROE is +0.59%, compared to SNY's ROE of +0.06%. Regarding short-term risk, NVO is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for NVO.Check SNY's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 202.9B. In comparison, GSK has a market cap of 102.5B. Regarding current trading prices, NVO is priced at $45.71 on the NYSE, while GSK trades at $51.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 11.37, whereas GSK's P/E ratio is 11.05. In terms of profitability, NVO's ROE is +0.59%, compared to GSK's ROE of +0.24%. Regarding short-term risk, NVO is more volatile compared to GSK. This indicates higher risk in terms of short-term price fluctuations for NVO.Check GSK's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 202.9B. In comparison, ZTS has a market cap of 31B. Regarding current trading prices, NVO is priced at $45.71 on the NYSE, while ZTS trades at $73.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 11.37, whereas ZTS's P/E ratio is 11.24. In terms of profitability, NVO's ROE is +0.59%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, NVO is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for NVO.Check ZTS's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 202.9B. In comparison, BIIB has a market cap of 30.9B. Regarding current trading prices, NVO is priced at $45.71 on the NYSE, while BIIB trades at $212.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 11.37, whereas BIIB's P/E ratio is 13.20. In terms of profitability, NVO's ROE is +0.59%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, NVO is more volatile compared to BIIB. This indicates higher risk in terms of short-term price fluctuations for NVO.Check BIIB's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 202.9B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, NVO is priced at $45.71 on the NYSE, while HZNP trades at $116.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 11.37, whereas HZNP's P/E ratio is 61.86. In terms of profitability, NVO's ROE is +0.59%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, NVO is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for NVO.Check HZNP's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 202.9B. In comparison, GRFS has a market cap of 6.6B. Regarding current trading prices, NVO is priced at $45.71 on the NYSE, while GRFS trades at $7.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 11.37, whereas GRFS's P/E ratio is 8.90. In terms of profitability, NVO's ROE is +0.59%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, NVO is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for NVO.Check GRFS's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 202.9B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, NVO is priced at $45.71 on the NYSE, while OGN trades at $13.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 11.37, whereas OGN's P/E ratio is 4.08. In terms of profitability, NVO's ROE is +0.59%, compared to OGN's ROE of +0.23%. Regarding short-term risk, NVO is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for NVO.Check OGN's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 202.9B. In comparison, CELG-RI has a market cap of 224.5M. Regarding current trading prices, NVO is priced at $45.71 on the NYSE, while CELG-RI trades at $0.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 11.37, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, NVO's ROE is +0.59%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, NVO is more volatile compared to CELG-RI. This indicates higher risk in terms of short-term price fluctuations for NVO.Check CELG-RI's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 202.9B. In comparison, CTOR has a market cap of 67M. Regarding current trading prices, NVO is priced at $45.71 on the NYSE, while CTOR trades at $0.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 11.37, whereas CTOR's P/E ratio is -1.53. In terms of profitability, NVO's ROE is +0.59%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, NVO is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for NVO.Check CTOR's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 202.9B. In comparison, SCLX has a market cap of 53.8M. Regarding current trading prices, NVO is priced at $45.71 on the NYSE, while SCLX trades at $6.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 11.37, whereas SCLX's P/E ratio is -0.16. In terms of profitability, NVO's ROE is +0.59%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, NVO is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for NVO.Check SCLX's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 202.9B. In comparison, SCLXW has a market cap of 44.7M. Regarding current trading prices, NVO is priced at $45.71 on the NYSE, while SCLXW trades at $0.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 11.37, whereas SCLXW's P/E ratio is N/A. In terms of profitability, NVO's ROE is +0.59%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, NVO is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for NVO.Check SCLXW's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 202.9B. In comparison, MIRA has a market cap of 32.1M. Regarding current trading prices, NVO is priced at $45.71 on the NYSE, while MIRA trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 11.37, whereas MIRA's P/E ratio is -0.53. In terms of profitability, NVO's ROE is +0.59%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, NVO is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for NVO.Check MIRA's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 202.9B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, NVO is priced at $45.71 on the NYSE, while BDSIW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 11.37, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, NVO's ROE is +0.59%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, NVO is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for NVO.Check BDSIW's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 202.9B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, NVO is priced at $45.71 on the NYSE, while CRXT trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 11.37, whereas CRXT's P/E ratio is -0.02. In terms of profitability, NVO's ROE is +0.59%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, NVO is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for NVO.Check CRXT's competition here